Please use this identifier to cite or link to this item:
|Title:||Management of hydroxyurea resistant or intolerant polycythemia vera.|
|Epworth Authors:||Raman, Indu|
|Other Authors:||Pasricha, Sant-Rayn|
|Keywords:||PEGylated Interferon Alpha|
Molecular Oncology and Cancer Immunology, Epworth Healthcare, Melbourne, Australia.
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
|Publisher:||Taylor & Francis|
|Citation:||2021 May 5;1-14.|
|Abstract:||Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis. Aspirin and hematocrit reduction by venesection or cytoreductive therapy are at the cornerstone of management. First line cytoreductive therapy in high-risk patients is hydroxyurea; however, its use is associated with toxicities and resistance in a significant proportion of patients. In a disease with a long overall survival with appropriate treatment, it is imperative that other treatment options do not accelerate the risk of progression to acute leukemia. The following review will appraise the evidence of interferon, ruxolitinib, and other agents in management of hydroxyurea resistant or intolerant polycythemia vera.|
|Journal Title:||Leukemia & Lymphoma|
|Affiliated Organisations:||Walter and Eliza Hall Institute, Melbourne, Australia.|
Peter MacCallum Cancer Institute, Melbourne, Australia.
|Type of Clinical Study or Trial:||Review|
|Appears in Collections:||Cancer Services|
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.